News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
206,197 Results
Type
Article (9265)
Company Profile (14)
Press Release (196918)
Section
Business (80135)
Career Advice (444)
Deals (11831)
Drug Delivery (18)
Drug Development (24570)
Employer Resources (53)
FDA (4591)
Job Trends (4390)
News (120430)
Policy (9065)
Tag
Academia (707)
Alliances (14645)
Alzheimer's disease (385)
Approvals (4587)
Artificial intelligence (36)
Bankruptcy (70)
Best Places to Work (3618)
Cancer (240)
Career advice (374)
Cell therapy (44)
Clinical research (19926)
Collaboration (81)
COVID-19 (669)
C-suite (21)
Data (228)
Diabetes (36)
Diagnostics (2079)
Earnings (42428)
Employer resources (48)
Events (29039)
Executive appointments (65)
FDA (4692)
Funding (43)
Gene therapy (29)
GLP-1 (156)
Government (1080)
Healthcare (5496)
Infectious disease (684)
Inflammatory bowel disease (32)
Interviews (63)
IPO (5925)
Job creations (870)
Job search strategy (347)
Layoffs (75)
Legal (1726)
Liver cancer (20)
Lung cancer (61)
Manufacturing (33)
Medical device (4456)
Medtech (4456)
Mergers & acquisitions (5902)
Metabolic disorders (67)
Neuroscience (439)
NextGen Class of 2024 (1686)
Non-profit (1239)
Northern California (267)
Obesity (36)
Opinion (36)
Parkinson's disease (27)
People (19535)
Phase I (5370)
Phase II (8476)
Phase III (7571)
Pipeline (80)
Postmarket research (878)
Preclinical (2196)
Radiopharmaceuticals (87)
Rare diseases (32)
Real estate (1595)
Recruiting (20)
Regulatory (6589)
Research institute (680)
Resumes & cover letters (64)
Southern California (279)
Startups (853)
United States (2676)
Vaccines (141)
Date
Today (26)
Last 7 days (170)
Last 30 days (696)
Last 365 days (10749)
2024 (8501)
2023 (12388)
2022 (17011)
2021 (18193)
2020 (17029)
2019 (14647)
2018 (11295)
2017 (11605)
2016 (10647)
2015 (13018)
2014 (9123)
2013 (7068)
2012 (7752)
2011 (8147)
2010 (7101)
Location
Africa (262)
Arizona (27)
Asia (14562)
Australia (2687)
California (614)
Canada (338)
China (74)
Connecticut (23)
Delaware (20)
Europe (35931)
Florida (94)
Georgia (21)
Idaho (24)
Illinois (60)
Indiana (42)
Japan (28)
Kansas (23)
Maine (30)
Maryland (108)
Massachusetts (456)
Michigan (42)
Minnesota (64)
New Hampshire (20)
New Jersey (237)
New York (161)
North Carolina (201)
Northern California (267)
Ohio (28)
Pennsylvania (162)
South America (443)
Southern California (279)
Texas (67)
Washington State (82)
206,197 Results for "janssen cilag international nv".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.
May 1, 2024
·
14 min read
MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (“Janssen PMP”) are pleased to announce a significant expansion to their existing Exclusive Evaluation and Option Agreement
September 6, 2023
·
9 min read
MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership
MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”), and JANSSEN PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
May 23, 2023
·
7 min read
Business
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
January 8, 2024
·
2 min read
Press Releases
QIAGEN N.V. to release results for Q3 2024 and hold webcast
October 10, 2024
·
1 min read
Pharm Country
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
NanoViricides, Inc. reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models.
June 11, 2024
·
9 min read
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
April 17, 2024
·
3 min read
Press Releases
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
October 1, 2024
·
11 min read
Pharm Country
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model.
May 20, 2024
·
7 min read
Pharm Country
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides, Inc. reports on the highly desirable blood concentration profile of its lead clinical stage broad-spectrum antiviral agent NV-387 upon intravenous administration in a non-human primate animal model.
June 4, 2024
·
8 min read
1 of 20,620
Next